Stephen Kimmell
Optometrist · Lafayette, INNPI 1427165893
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Biotissue Holdings Inc. accounts for 70.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $8,341 and has fallen 62.5% since, to $3,128 in 2025. Among optometrist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $97.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$14K
- Sun Pharmaceutical Industries Inc.$2K
- Tarsus Pharmaceuticals, Inc.$705
- Alcon$632
- Dompe US, Inc.$523
- AbbVie$436
- plus $2K from 17 others
What the payments were for
- Consulting fees$10,34352%
- Speaking & faculty fees$2,00010%
- Travel & lodging$2,05010%
- Food & beverage$5,52728%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 46 | $14,058 |
| Sun Pharmaceutical Industries Inc. | 14 | $1,718 |
| Tarsus Pharmaceuticals, Inc. | 23 | $705 |
| Alcon | 18 | $632 |
| Dompe US, Inc. | 12 | $523 |
| AbbVie(2 entities) | 21 | $436 |
| Rxsight Inc | 16 | $389 |
| Mallinckrodt Hospital Products Inc. | 9 | $304 |
| Bausch & Lomb Americas Inc. | 9 | $285 |
| Glaukos Corporation | 4 | $237 |
| Lensar, Inc. | 4 | $141 |
| Amgen(2 entities) | 7 | $116 |
| Novartis | 4 | $88 |
| Harrow Eye, LLC | 3 | $83 |
| Kala Pharmaceuticals, Inc. | 4 | $62 |
| Thea Pharma Inc. | 3 | $59 |
| Ocular Therapeutix, Inc. | 3 | $46 |
| Quidel Corporation | 1 | $36 |
| Oyster Point Pharma, Inc. | 1 | $29 |
| Lombart Brothers, Inc. | 1 | $23 |
| Omeros Corporation | 1 | $22 |
| Tearlab Corp | 1 | $13 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$3,042
- XELPROS$1,486
- AmnioGraft$1,042
- XDEMVY$392
- CEQUA$286
- RADIUS$136
- Oxervate$124
- BROMSITE$124
- Rocklatan$124
- Rhopressa$124
- RXSIGHT CONTACT LENS$115
- RXSIGHT INJECTOR CARTRIDGE$115
- RXSIGHT INJECTOR HANDPIECE$115
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$115
- LIGHT ADJUSTABLE LENS (LAL)$115
- MIEBO$107
How this compares
$20,018 in reported general payments places this provider in the 95th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 24 | $1,349,277 |
| XdemvyLotilaner | 190 | $350,463 |
| RestasisCyclosporine | 120 | $123,754 |
| XiidraLifitegrast | 63 | $81,148 |
| RocklatanNetarsudil Mesylat/Latanoprost | 129 | $53,468 |
| LumiganBimatoprost | 97 | $50,742 |
| VevyeCyclosporine | 45 | $33,483 |
| Cyclosporine | 34 | $18,291 |
| VyzultaLatanoprostene Bunod | 31 | $13,975 |
| TyrvayaVarenicline Tartrate | 18 | $11,558 |
| MieboPerfluorohexyloctane/Pf | 12 | $10,103 |
| Prednisolone Acetate | 173 | $6,898 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $6,705 |
| Latanoprost | 508 | $6,223 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $523 | $1,349,27724 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $705 | $350,463190 claims |
| AbbVieRestasis, Lumigan, Combigan | $436 | $179,434229 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $285 | $105,227106 claims |
| Harrow Eye, LLCVevye | $83 | $33,48345 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $29 | $11,55818 claims |
| AlconSimbrinza | $632 | $2,44812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,318 optometrist providers in Indiana.
Other optometrist in Lafayette
- Damon DierkerIndianapolis$707K
- Jason JedlickaBloomington$456K
- Kari RiinaFishers$308K
- Rhonda RobinsonIndianapolis$205K
- John CzajaMerrillville$189K
- Peter KollbaumBloomington$60K
- Ryan GustusBluffton$48K
- Steve VargoHighland$48K
- Helen TzanetakosMunster$47K
- Nicholas McColleyGreenfield$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.